Dana-Farber Cancer Institute Jul 10 2025 Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVax MI  is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.  The findings are published in  Cell . We believe that the immunogenicity of current personalized cancer vaccines, considered critical for